Ken joined Prosonix' Board of Directors as a Director in August 2011 and became Non-executive Chairman in November 2012. He is also the Chair of the Advisory Board. Ken has over 20 years' experience in the pharmaceutical industry. He is Executive Chairman of PolyTherics Ltd and until August 2010 was CEO of Skyepharma plc. Before that he was Chief Executive Officer of Arakis Ltd, Vice-President European Affairs at Alza Corporation and Vice-President Clinical Development at Sequus Inc. Prior to this he held a variety of clinical development and commercial strategy roles at GlaxoWellcome plc and Warner-Lambert earlier in his career. Ken is also a Non-Executive Director of Xention Ltd. He holds a medical degree from St Mary's, Imperial College, London University.
David is a co-founder of Prosonix and has led the Company as CEO since its establishment in 2006, raising more than £22 million from international life sciences investors. Prior to Prosonix, he was General Manager of the C3 Technology Business of Accentus, which he established after joining them in 2002. David has more than 20 years of business development experience concerning cutting-edge technologies in high growth, complex, intellectual property-rich environments, with a prime focus on the pharmaceutical industry. He has also held a number of senior positions in Dow Pharma, Ascot plc, ChiroTech Ltd, and Air Products plc. David holds a BSc in Chemical Engineering.
Andy is a co-founder of Prosonix and, as COO/CFO, has managed the establishment, development and profitable growth of the business since formation in 2006 to deliver key strategic elements of the business plan. Andy has nearly 25 years' experience in international business management, including both operational capability development and financial control, while supporting major commercial deal making. Prior to joining Prosonix, he was Operations Manager of the C3 Technology Business of Accentus and previously held senior positions in two AEA Technology businesses in change management and business transformation roles. Before that he enjoyed a highly successful 18-year career in BOC spanning technical, operations and commercial management and was responsible for winning several long-term, multi-million pound business contracts. Andy holds a Bachelors' Degree in Chemical Engineering and is a Chartered Engineer. He also holds a Masters' Degree in Business Administration.
Cécile has extensive business development and commercial experience within the pharmaceutical, biotechnology and generics sector, and strong global networks. She joined Prosonix from the Watson group (now known as Actavis, Inc.), the world's third-largest generics company, where she was Commercial Director EU. Before Watson, Cécile was Executive Director of Commercial Development at Ark Therapeutics, Executive Director of Global Business Development at Pliva, and Head of the European Division at Ranbaxy Laboratories Ltd. She also spent several years in a variety of commercial roles at Fisons plc.
Frank is President and Chief Executive Officer of Columbia Laboratories, Inc., a NASDAQ-listed speciality pharmaceutical company, and Non-executive Chairman of Skyepharma plc, a London-listed speciality drug delivery company. He was CEO of Skyepharma between 2006 and 2008, President of European Operations and Managing Director, UK at IVAX Corporation from 2002 to 2006, and President and Chief Executive Officer of Faulding Pharmaceutical Co., from 2000 to 2001. Previously, he was Vice-President of Specialty Care Products at Roche and Vice-President and General Manager of the Lederle unit of American Home Products (now part of Pfizer, Inc.). He holds a MBA degree and a BSc degree in pharmacy from Northeastern University (Boston, MA, USA).
Karl joined Gimv in 2011 and is a Venture Capital Partner in the Life Sciences team. Prior to joining Gimv he worked as General Partner with Ventech, a Paris-based Europe and China focused VC fund where he led investments into Covagen, Funxional Therapeutics, Themis and Prosonix and served on the boards of those companies. He also served on the board of Actogenix. Between 2002 and 2009, Karl was at Atlas Venture (London and Munich), a transatlantic venture fund, where he was instrumental in the formation and/or financing of several start-ups across Europe, including U3 Pharma (acquired by Daiichi Sankyo) and Nitec Pharma (acquired by Horizon Pharma). Previously, he worked as a Scientific Fellow at the CNRS for Neurochemistry in Strasbourg (France). Karl holds a PhD in molecular neurobiology from the Max-Delbrück-Center for Molecular Medicine Berlin (Germany) and a diploma in Biology from the Free University of Berlin.
Mounia is Venture Partner at Ventech, driving Ventech Life Science investments since 2001. Mounia is also General Partner at Turenne Capital, a growth capital fund specialized in Healthcare. She started her career as analyst in the Life Sciences team at Atlas Venture, a venture capital firm. Then she conducted strategic audits covering both organizational and technical aspects at Altran. She also performed due diligence procedures on behalf of financial investors and has been involved in fundraising for funds and start-ups. Mounia has sat or is still sitting on the boards of Actogenix, BioVex (acquired by Amgen for $1 billion), Cellerix (now EBR: TIGENIX), Covagen, Eyegate, Funxional Therapeutics (acquired by Boehringer Ingelheim), Inserm Transfert Initiative, Laboratoires Sebbin, Scynexis, Tigenix and Xytis. Mounia graduated as an engineer from École Centrale de Paris and holds a PhD in Molecular Biophysics.
Edwin is a Senior Partner at Gilde Investment Management, which he joined in 1997. He became investment manager of Gilde Strategic Situations Fund - a fund of funds - and was involved with investments in funds managed by AXA (France), Amadeus (UK), Technologie Holding (now 3i, Germany) and OneLiberty Ventures (now Flagship Ventures, US). In 1998 he was appointed investment manager and later investment director of Gilde Healthcare I. Edwin received EVCJ's "Venture Realization of the Year - Life Science award" in 2005 for the sale of GlycArt to Roche. Previously, he served for three years as a tax consultant in the International Tax department of Coopers & Lybrand in the Netherlands, specializing in VAT. Edwin holds a Masters' Degree in Business and Fiscal Economics from Erasmus University in Rotterdam.
Klaas is the Managing Partner of the Entrepreneurs Fund, which he joined in 2006. He previously created and led a corporate venturing team at Vanenburg Group whose investments included WebEx, afterwhich he spent time as a consultant with McKinsey & Company in both Amsterdam and St Petersburg. Klaas has an MSc in Physics and an MBA from Insead.